Literature DB >> 17623621

Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice.

Rita Wickham1.   

Abstract

Advances in supportive care have increased the likelihood that previously less common adverse effects of chemotherapy will be more evident. The incidence of chemotherapy-induced peripheral neuropathy (CIPN) is increasing because more neurotoxic drugs have been developed and because patients are living longer and receiving multiple chemotherapy regimens. This article reviews the anatomy of the peripheral nervous system, the proposed mechanisms of CIPN, and manifestations of CIPN from vinca alkaloids, taxanes, and platinum analogs. Major topics of this article are evidence-based data regarding symptom management, a review of medical management, and a synthesis of nursing care for patients at risk for or experiencing CIPN.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17623621     DOI: 10.1188/07.CJON.361-376

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  19 in total

Review 1.  What about Alice? Peripheral neuropathy from taxane-containing treatment for advanced nonsmall cell lung cancer.

Authors:  Celia M Bridges; Ellen M Lavoie Smith
Journal:  Support Care Cancer       Date:  2014-06-21       Impact factor: 3.603

2.  Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.

Authors:  Rhonda J Moore; Hunter Groninger
Journal:  Cureus       Date:  2013-06-14

3.  Pain, neuropathic symptoms, and physical and mental well-being in persons with cancer.

Authors:  Cindy S Tofthagen; Susan C McMillan
Journal:  Cancer Nurs       Date:  2010 Nov-Dec       Impact factor: 2.592

4.  Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy.

Authors:  Delma Aurélia da Silva Simão; Antônio Lúcio Teixeira; Raissa Silva Souza; Elenice Dias Ribeiro de Paula Lima
Journal:  Support Care Cancer       Date:  2014-05-09       Impact factor: 3.603

5.  Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management.

Authors:  Cindy Tofthagen; Constance M Visovsky; Rachelle Hopgood
Journal:  Clin J Oncol Nurs       Date:  2013-04       Impact factor: 1.027

6.  Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

Authors:  Joseph D Tariman; Ginger Love; Emily McCullagh; Stacey Sandifer
Journal:  Clin J Oncol Nurs       Date:  2008-06       Impact factor: 1.027

7.  Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Kelly N H Nudelman; Brenna C McDonald; Yang Wang; Dori J Smith; John D West; Darren P O'Neill; Noah R Zanville; Victoria L Champion; Bryan P Schneider; Andrew J Saykin
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

8.  Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer.

Authors:  Marta Vallee Cobham; Diana Donovan
Journal:  Cancer Manag Res       Date:  2009-06-29       Impact factor: 3.989

9.  Increased interleukin-6 activity associated with painful chemotherapy-induced peripheral neuropathy in women after breast cancer treatment.

Authors:  Angela Starkweather
Journal:  Nurs Res Pract       Date:  2010-08-10

Review 10.  Physical therapy interventions, other than general physical exercise interventions, in children and adolescents before, during and following treatment for cancer.

Authors:  Paula A Ospina; Alyssa McComb; Lesley E Pritchard-Wiart; David D Eisenstat; Margaret L McNeely
Journal:  Cochrane Database Syst Rev       Date:  2021-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.